Article
Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease
27 Jun 2022
Abstract excerpt
In this article, the authors focus on the management of patients with MET exon 14 skipping alterations by addressing the biology of the MET receptor and exon 14 skipping mutations, current treatment strategies, and sequential treatment options based on resistance mechanisms to MET inhibitors in patients with non-small-cell lung cancer.
Topics
Join the communities discussing this publication.